Abstract 2187
Background
The number of Chinese cancer survivors is increasing due to the trend of an aging population and improved cancer survival. It is urgently required to estimate the health status of cancer survivors and provide scientific evidence for future health care reform. This study aimed to evaluate the general health status of cancer survivors older than 45 years in China.
Methods
We identified cancer survivors (n = 354) and participants without cancer (n = 16,664) in the China Health and Retirement Longitudinal Study (CHARLS). Physical and mental health information collected by questionnaire were compared between cancer survivors and cancer-free controls.
Results
The mean age of cancer survivors was 61.0 years. More cancer survivors were female (68.9% vs. 52.3%, P < 0.001) and lived in a rural region (43.8% vs. 38.4%, P = 0.039) than those without cancer. Cancer survivors and participants without cancer did not show significant differences in age, marital status, education or BMI. The health status of middle-aged and older cancer survivors are shown in the table. Cancer survivors had more concomitant chronic diseases than participants without cancer (2.75 vs. 2.00, P < 0.001). The current health condition reported by cancer survivors themselves was poorer than no cancer group (3.87 vs. 3.38, P < 0.001). The daily activity score was higher in the cancer group (3.53 vs. 2.39, P < 0.001), which indicated that cancer survivors had more difficulties in their daily life than other middle-aged and older participants. There was no statistically significant difference in cognitive function between these two groups even after adjustment (12.61 vs. 12.90, P = 0.612). Cancer survivors had more depressive symptoms than participants without cancer after adjustment (10.07 vs. 8.01, P = 0.003).Table: 1649P
Health status of middle-aged and older cancer survivors and participants without cancer from the CHARLS
Characteristic | Total (N = 17,018) | Cancer survivors (n = 354) | No cancer (n = 16,664) | P value | P value† |
---|---|---|---|---|---|
Number of concomitant chronic diseases, mean ± SD | 2.02 ± 1.70 | 2.75 ± 2.13 | 2.00 ± 1.69 | <0.001 | |
Self-reported health score (1-5), mean ± SD | 3.39 ± 0.38 | 3.87 ± 0.82 | 3.38 ± 0.87 | <0.001 | <0.001 |
Daily activity, mean ± SD | 2.41 ± 3.36 | 3.53 ± 3.85 | 2.39 ± 3.35 | <0.001 | <0.001 |
Cognitive function, mean ± SD | 12.89 ± 5.69 | 12.61 ± 5.60 | 12.90 ± 5.69 | 0.629 | 0.612 |
Depression, mean ± SD | 8.05 ± 6.41 | 10.07 ± 7.06 | 8.01 ± 6.39 | <0.001 | 0.003 |
Adjusted for age, sex, region, and number of concomitant chronic diseases.
Conclusions
The health status of middle-aged and older cancer survivors is poor in China. High-quality and cost-effective supportive care for these individuals is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China (No. 61435001) and CAMS Innovation Fund for Medical Sciences (No. 2016-I2M-1-001, No. 2017-I2M-4-003).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5218 - Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
Presenter: Bram De Laere
Session: Poster Display session 3
Resources:
Abstract
2452 - High proportion of multiple KRAS mutations in circulating tumor DNA and tumor tissue of pancreatic ductal adenocarcinoma
Presenter: Min Kyeong Kim
Session: Poster Display session 3
Resources:
Abstract
3328 - Biological difference of tumor mutational burden (TMB) and microsatellite instability (MSI) status in patients (pts) with somatic vs. germline BRCA1/2-mutated advanced gastrointestinal (GI) cancers using cell-free DNA (cfDNA) sequencing analysis in the GOZILA study
Presenter: Yasuyuki Kawamoto
Session: Poster Display session 3
Resources:
Abstract
3022 - Cell-Free DNA to Detect Focal Versus Non-Focal MET Amplification in Metastatic Colorectal Cancer Patients: Combined Analysis from Japan and the United States
Presenter: Mishima Saori
Session: Poster Display session 3
Resources:
Abstract
2833 - Presence of circulating tumor DNA in surgically resected renal cell carcinoma is associated with advanced disease and poor patient prognosis
Presenter: Andres Correa
Session: Poster Display session 3
Resources:
Abstract
1376 - Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (cfDNA) for cancer diagnosis and recurrence-risk assessment in early-stage lung cancer
Presenter: Junghee Lee
Session: Poster Display session 3
Resources:
Abstract
4050 - DEMo: a prospective evaluation of a prognostic clinico-molecular composite score in NSCLC patients treated with immunotherapy.
Presenter: Arsela Prelaj
Session: Poster Display session 3
Resources:
Abstract
4727 - Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)
Presenter: Cindy Yang
Session: Poster Display session 3
Resources:
Abstract
3662 - Dynamic changes in whole-genome cell-free DNA (cfDNA) to identify disease progression prior to imaging in advanced solid tumors
Presenter: Andrew Davis
Session: Poster Display session 3
Resources:
Abstract
3817 - Evaluation of Microsatellite Instability Testing Through cell-free DNA sequencing
Presenter: Shile Zhang
Session: Poster Display session 3
Resources:
Abstract